Applicant, as named in the Orange Book

Exelixis

Next listed expiry: Cometriq on 10 Feb 2032. 1 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Cometriq · 2 strengths cabozantinib s-malate	cabozantinib s-malate	203756	10 Feb 2032	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.